By creating a double JNK3-SMNΔ7 knockout (KO) mouse model, the authors obtained a milder SMA phenotype, demonstrating that JNK pathway might represent a potential SMN-independent therapeutic target for the treatment of SMA. This evidence concerns the gene MAPK10 and proximal spinal muscular atrophy.